Breaking News: Historical Drop of DR-TB Treatment Cost Below $300 After Third Major Cut in 2025 by Stop TB’s Global Drug Facility | Stop TB Partnership
The Stop TB Partnership’s Global Drug Facility (GDF) has announced a 30% price reduction for bedaquiline produced by Lupin, now available at just $63 per treatment course. This latest decrease brings the lowest cost of the full BPaLM regimen—the most widely recommended treatment for drug-resistant tuberculosis (DR-TB)—below $300 for the first time, now priced at $284 per course. The bedaquiline price cut is projected to generate over $4.5 million in annual savings for GDF clients and high-burden countries that reference GDF prices in their own procurement negotiations. Savings from this price reduction alone could enable the purchase of 71,000 additional bedaquiline courses or 16,000 full BPaLM treatment regimens each year. This announcement follows two earlier price reductions in 2025: Together, these are the third consecutive price reductions over a 6-month period by GDF for key DR-TB medicines, dramatically improving affordability and access. In total, six WHO-recommended DR-TB regi
NEWS ALERT 3 September 2025 | Geneva, Switzerland Life-Saving DR-TB Treatments Even More Affordable Following Newest Bedaquiline Price Decrease The Stop TB Partnership’s Global Drug Facility (GDF) has announced a 30% price reduction for bedaquiline produced by Lupin, now available at just $63 per treatment course . This latest decrease brings the lowest cost of the full BPaLM regimen —the most widely recommended treatment for drug-resistant tuberculosis (DR-TB)— below $300 for the first time , now priced at $284 per course. The bedaquiline price cut is projected to generate over $4.5 million i
Explore this link on the map →saved by
related reading
- Huntington's disease successfully treated for first timebbc.com
- How Advocates Pushed Big Pharma to Cut Tuberculosis Drug Prices | Scientific Americanscientificamerican.com
- Adapting TB Programs to Face the Challenge of COVID-19: Lessons From the Philippines - Stories - The Global Fund to Fight AIDS, Tuberculosis and Malariatheglobalfund.org
- New Genzyme pill will cost patients $310,250 a year - The Boston Globeweb.archive.org
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan - PubMedpubmed.ncbi.nlm.nih.gov
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
- How PBMs can use private-labelled drug products as a great escape from anti-steering policies - 46brooklyn Research46brooklyn.com
- Joe Biden Lowered Drug Prices. Does Anyone Care? - The Atlantictheatlantic.com